November 26, 2025
Why this week matters for banking interviews
This is the kind of market backdrop where interview answers get better if you can connect micro stories to macro pressure. The big themes weren’t just “AI is volatile” or “rates may fall.” The cleaner read is that investors are starting to separate durable growth, balance sheet risk, policy exposure, and consolidation logic.
For finance students, that’s useful. A good investment banking interview answer doesn’t need to predict the market. It needs to explain why companies are doing deals, why investors are rewarding or punishing certain stories, and how financing conditions affect strategic decisions.
The strongest discussion points this week came from four places: Nvidia’s earnings-driven reversal, Eli Lilly’s GLP-1 momentum, several scale-driven M&A transactions, and the renewed pressure in crypto and long-duration growth assets.
Nvidia beat, then the market faded the rally
Nvidia reported a 62% jump in AI data-center chip sales and raised its quarterly outlook. That initially looked like enough to spark a broader rally, with the Nasdaq up as much as 2.6% early in the session.
Then the market reversed hard. Nvidia erased a 5% morning gain and closed down 3%. The Nasdaq fell 2.2%, the S&P 500 dropped 1.6%, and the Dow finished 387 points lower.
That reversal is a useful interview talking point because it shows how earnings beats don’t always solve valuation anxiety. Investors weren’t only asking whether Nvidia could grow. They were asking whether the broader AI ecosystem can keep funding massive chip and data center spending without straining balance sheets or producing disappointing returns.
Other AI-linked names sold off as well. Micron fell 11%, Western Digital dropped 8.9%, and AMD slid 7.8%. Credit stress also entered the conversation, with default-protection costs on Oracle bonds rising nearly 50% since mid-October. That detail matters. Equity markets can celebrate growth for a while, but credit markets tend to ask a colder question: who is paying for all of this?
If you’re asked about AI in an interview, avoid a generic answer like “AI is changing everything.” A sharper answer is that AI demand remains real, but the market is increasingly focused on capital intensity, customer concentration, financing structure, and whether returns on invested capital can justify the spending cycle.
The macro picture is less clean than a simple rate-cut story
The delayed September jobs report showed the U.S. added 119,000 jobs, above expectations, while unemployment unexpectedly rose to 4.4%. That combination gave investors mixed signals. It wasn’t weak enough to guarantee aggressive easing, but it wasn’t strong enough to erase growth concerns either.
Rate-cut odds for December sat near 40%, up from 30% the prior day but far below the nearly 99% probability priced in a month earlier. The 10-year Treasury yield ended around 4.1%.
Bonds have been one of the cleaner beneficiaries of the shifting macro backdrop. The Bloomberg U.S. Aggregate Bond Index was up about 6.7% for the year, helped by falling rates, a cooling economy, and two Federal Reserve cuts already in 2025. The 10-year yield had fallen nearly half a percentage point during the year.
But even here, the story isn’t risk-free. Investment-grade spreads recently fell to their lowest levels since the late 1990s, and the federal budget deficit was about $1.8 trillion. So while lower rates can support bond prices and risk assets, tighter spreads and heavy government borrowing create their own vulnerabilities.
For interviews, this is a good way to show balance. Lower rates can improve valuation multiples and reduce financing costs, but they don’t automatically remove credit risk or justify every long-duration asset.
Crypto’s selloff is really a risk appetite story
Bitcoin had lost nearly 30% of its value since October 6, and the total crypto market decline exceeded $1 trillion. Bitcoin was around $91,700 per token and roughly flat since January.
The interesting part isn’t just the move in Bitcoin. It’s how crypto weakness lined up with broader pressure in speculative assets. A Goldman Sachs index of unprofitable tech companies had dropped 19% since reaching a high on October 15, and retail activity in U.S. equities had clearly pulled back since mid-October. Defensive ETF flows increased during the same period.
That’s a useful framing: crypto can act like a high-beta read on liquidity and retail risk appetite. When investors become less comfortable with stretched valuations, uncertain Fed policy, or crowded growth trades, crypto often feels that pressure quickly.
At the same time, traditional finance is still building crypto products. Morgan Stanley sold $104 million of structured notes tied to BlackRock’s iShares Bitcoin Trust. The notes gave wealthy clients exposure to Bitcoin through a defined payoff structure: if the ETF closed at or above its initial level after a year, the note would automatically return principal plus 28%. But if the ETF fell below 75% of its initial price, investors faced a full loss with no protection.
That’s a great product discussion for private wealth, structured products, or capital markets interviews. The demand isn’t just “buy Bitcoin.” It’s controlled exposure, yield enhancement, and downside boundaries, even if the protection is conditional.
Eli Lilly shows why healthcare growth can trade like a mega-cap tech story
Eli Lilly’s weight-loss drug momentum is one of the strongest single-company stories in the market. The company has built a major position in GLP-1 obesity treatment, with Zepbound pulling ahead of Novo Nordisk’s Wegovy, helped by increased production and emerging clinical data.
The setup is interesting because Lilly’s growth story is not tied to AI sentiment or the cloud infrastructure capex cycle. It’s tied to obesity drug technology, market expansion, production capacity, and reimbursement.
Lilly began selling Zepbound in 2023, and the FDA declared in 2024 that there was no longer a shortage in obesity treatment drug supply. The company has also benefited from a policy development: the Trump administration struck a deal with major GLP-1 drugmakers to lower prices in exchange for broader Medicare and Medicaid coverage. According to Lilly, that could expand access to more than 40 million Americans.
For banking interviews, this is a strong healthcare sector answer because it combines volume growth, pricing, access, policy, and patent risk. The biggest long-term concern is the patent cliff. Once Zepbound loses patent protection, revenue pressure could be significant. One analyst described it as potentially “the biggest patent cliff of all time.”
That’s the trade-off in one sentence: Lilly has exceptional growth visibility today, but the durability of that growth depends on patent life, competitive dynamics, and continued innovation.
M&A activity points to scale, specialization, and sponsor appetite
Akzo Nobel and Axalta: coatings consolidation
Akzo Nobel agreed to acquire Axalta Coating Systems in a transaction that would create a combined paint and coatings company with nearly $17 billion in annual sales and an enterprise value of $25 billion. Akzo Nobel shareholders will own 55% of the combined company, which will trade on the New York Stock Exchange. Akzo Nobel shareholders will also receive a €2.5 billion special dividend, while each Axalta shareholder will receive 0.6539 Akzo Nobel shares.
The strategic rationale is classic industrial consolidation: scale, cost savings, and better positioning in a tougher operating environment. The companies expect about $600 million in cost savings, with 90% realized within three years.
This is exactly the kind of deal where you can discuss synergies in an interview. Cost synergies are likely to matter more than revenue synergies here, especially with tariffs and a slowing economy weighing on the coatings industry. The combined portfolio spans brands such as Dulux, Cuprinol, and Cromax across more than 160 countries.
Sealed Air: private equity still wants steady industrial cash flow
Sealed Air, best known for Bubble Wrap, agreed to be acquired by Clayton, Dubilier & Rice for an enterprise value of approximately $10.3 billion, including debt. Shareholders will receive $42.15 per share in cash, a nearly 41% premium to the unaffected share price from mid-August. The company is expected to be delisted after the deal closes, pending regulatory and shareholder approvals.
For sponsor interviews, this is a clean example of why private equity likes packaging and industrial platforms. Sealed Air serves more than 117 countries and generated about $5.4 billion in revenue in 2024 through food care and protection solutions. The appeal is relatively steady cash flow, operational improvement potential, and the ability to restructure away from public market scrutiny.
Amundi and ICG: private credit distribution gets more important
Amundi agreed to acquire a 9.9% economic interest in ICG as part of a long-term strategic partnership. The structure includes buying 4.64% of ICG’s ordinary shares in the market and subscribing to 5.26% in non-voting shares, with ICG launching a buyback to avoid dilution.
The bigger point is distribution. Under the 10-year agreement, Amundi becomes the exclusive global distributor, outside certain regions, of selected ICG evergreen private-markets products to wealth-management clients. The two firms will also co-develop private credit and private equity strategies for wealthy investors.
That’s a strong private markets theme: asset managers want private credit exposure, but they also need distribution channels that can reach wealth clients at scale.
Other sector notes worth keeping in your back pocket
- Energy: WTI settled 1.4% higher at $60.74 and Brent gained 1.1% to $64.89 as diesel and gasoil prices rallied. Nymex diesel rose 6.1% and ICE gasoil gained 7.1%, driven by concerns around distillate supply, Ukrainian strikes on Russian refineries, sanctions, and seasonal demand.
- Pharma manufacturing: CSL plans to invest about $1.5 billion in U.S. manufacturing to expand capacity for plasma-derived therapies. The move fits the broader push to bring drug production back to the U.S.
- AI partnerships: Microsoft, Nvidia, and Anthropic announced a partnership involving up to $30 billion in spending, with Nvidia and Microsoft each fronting more than $15 billion to Anthropic and Anthropic committing to purchase $30 billion of Microsoft Azure and Nvidia AI services.
- Defense: Rheinmetall remains a direct way to discuss Europe’s defense spending cycle. First-half revenue reached €4.7 billion, up roughly 24% versus the prior year, and order backlog increased by €14 billion year over year.
How I’d use this in an interview
If you only remember one thing, make it this: the market is still paying for scale and growth, but it’s becoming less forgiving about funding, valuation, and execution risk.
Lilly shows how a company can earn a premium when product demand, market expansion, and policy support line up. Akzo-Axalta shows how consolidation can create value when an industry faces tariffs, slower demand, and margin pressure. Sealed Air shows that sponsors still want durable cash-flow platforms. Nvidia’s reversal shows that even the best growth stories can stumble when investors question capital intensity and valuation.
That’s a much better interview answer than reciting index moves. Bankers care about what drives transactions, financing needs, and valuation debates. This week had plenty of all three.